National Alzheimer's Project Act

Last updated

The National Alzheimer's Project Act is an Act in the United States that was driven by the rapid increasing number of sufferers of Alzheimer's disease. [1] It resulted in a U.S. National Alzheimer's Plan for increased spending on scientific research, care, and public engagement.

Contents

Development

The National Alzheimer's Project Act was initially developed due to recommendations from a taskforce created in 2009, and was authored by Senator Susan Collins and Senator Evan Bayh, [2] before being signed into law by President Barack Obama on January 4, 2011. [3] [4] Named the 'Alzheimer's Study Group', the taskforce consisted of health policy experts and was co-chaired by former House Speaker Rep. Newt Gingrich and Sen. Bob Kerrey. They assessed the current status of response to the burden of Alzheimer's disease, looked at the current trajectory for coping with this burden, and determined whether current policy was sufficient. They concluded in their 52-page report, entitled 'A National Alzheimer’s Strategic Plan: The Report of the Alzheimer’s Study Group' that the 'national effort to address Alzheimer’s disease has lacked coordination and focus, and has been woefully underfunded relative to the scale of the mounting crisis'. [5]

Details

A National Plan to address Alzheimer's disease was subsequently released on May 15, 2012 by the U.S. Department of Health and Human Services. [4]

This national plan has 5 goals:

  1. Prevent and effectively treat Alzheimer's disease and related dementia by 2025
  2. Optimize Care Quality and Efficiency
  3. Expand Supports for People with Alzheimer's Disease and Their Families.
  4. Enhance Public Awareness and Engagement.
  5. Track Progress and Drive Improvement.

To inform the National Plan, the U.S. Department of Health and Human Services worked with the U.S. Department of Veterans Affairs (VA), the National Science Foundation (NSF), and the U.S. Department of Defense (DoD) to create an Interagency group. [6]

This group also consisted of Health and Human Services representatives from the following agencies:

Follow-up and output

Reports

Reports on each goal are generated yearly. [7]

Budgets

The National Alzheimer's Project Act recommended $2 billion a year to achieve their goal of preventing and treating Alzheimer's disease by 2025. In 2017, a bill was approved to boost government funding for Alzheimer's disease to almost $1.4 billion for the fiscal year. [7] In 2015, Congress requested that a 'professional judgement', or 'bypass' budget be created for Alzheimer's disease. This budget goes directly to Congress and the President, and in biomedicine has only been seen previously in the fields of cancer and AIDS. [8]

Global context

The existence of the National Alzheimer's Project Act means that the U.S. joins 31 other countries and territories around the world who have developed a plan for dementia. [9] In May 2017, the World Health Organization established a Global Action Plan for Dementia, focusing on the public health response. [10] [11] [12]

Related Research Articles

<span class="mw-page-title-main">Dementia</span> Long-term brain disorders causing impaired memory, thinking and behavior

Dementia is the general name for a decline in cognitive abilities that impacts a person's ability to perform everyday activities. This typically involves problems with memory, thinking, and behavior. Aside from memory impairment and a disruption in thought patterns, the most common symptoms include emotional problems, difficulties with language, and decreased motivation. The symptoms may be described as occurring in a continuum over several stages. Dementia ultimately has a significant effect on the individual, caregivers, and on social relationships in general. A diagnosis of dementia requires the observation of a change from a person's usual mental functioning and a greater cognitive decline than what is caused by normal aging.

<span class="mw-page-title-main">United States Department of Health and Human Services</span> Department of the US federal government

The United States Department of Health and Human Services (HHS) is a cabinet-level executive branch department of the U.S. federal government created to protect the health of the U.S. people and providing essential human services. Its motto is "Improving the health, safety, and well-being of America". Before the separate federal Department of Education was created in 1979, it was called the Department of Health, Education, and Welfare (HEW).

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

Lifelong learning is the "ongoing, voluntary, and self-motivated" pursuit of knowledge for either personal or professional reasons. It is important for an individual's competitiveness and employability, but also enhances social inclusion, active citizenship, and personal development.

<span class="mw-page-title-main">President's Emergency Plan for AIDS Relief</span> United States governmental initiative

The United States President's Emergency Plan For AIDS Relief (PEPFAR) is a United States governmental initiative to address the global HIV/AIDS epidemic and help save the lives of those suffering from the disease. Launched by U.S. President George W. Bush in 2003, as of May 2020, PEPFAR has provided about $90 billion in cumulative funding for HIV/AIDS treatment, prevention, and research since its inception, making it the largest global health program focused on a single disease in history until the COVID-19 pandemic. PEPFAR is implemented by a combination of U.S. government agencies in over 50 countries and overseen by the Global AIDS Coordinator at the United States Department of State. As of 2023, PEPFAR has saved over 25 million lives, primarily in sub-Saharan Africa.

<span class="mw-page-title-main">Diseases of affluence</span> Health conditions thought to be a result of increasing wealth in society

Diseases of affluence, previously called diseases of rich people, is a term sometimes given to selected diseases and other health conditions which are commonly thought to be a result of increasing wealth in a society. Also referred to as the "Western disease" paradigm, these diseases are in contrast to so-called "diseases of poverty", which largely result from and contribute to human impoverishment. These diseases of affluence have vastly increased in prevalence since the end of World War II.

The Alzheimer's Association is a nonprofit voluntary health organization that focuses on Alzheimer's disease care, support and research.

Alzheimer’s Disease International (ADI) is a not-for-profit, international federation of Alzheimer and dementia associations from around the world. The organization is in official relations with the World Health Organization (WHO). ADI advocates for people living with Alzheimer’s disease and all other types of dementia.

<span class="mw-page-title-main">Alzheimer's disease</span> Progressive neurodegenerative disease

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

<span class="mw-page-title-main">Alzheimer's Foundation of America</span> Non-profit organisation in the USA

The Alzheimer's Foundation of America (AFA) is an American nonprofit organization based in New York City whose mission is to provide support, services and education to individuals, families and caregivers affected by Alzheimer's disease and related dementias nationwide, and fund research for better treatment and a cure. AFA unites more than 2,000 member organizations from coast-to-coast that are dedicated to meeting the educational, social, emotional and practical needs of individuals with Alzheimer's disease and related illnesses, and their caregivers and families. Member organizations include grassroots Alzheimer's agencies, senior centers, adult daycare center, home healthcare agencies, long-term care residences, research facilities, and other dementia-related groups. AFA holds Charity Navigator's highest rating of 4 stars.

Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease (AD). It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion.

Geriatric psychology is a subfield of psychology that specializes in the mental and physical health of individuals in the later stages of life. These specialized psychologists study a variety of psychological abilities that deplete as aging occurs such as memory, learning capabilities, and coordination. Geriatric psychologists work with elderly clients to conduct the diagnosis, study, and treatment of certain mental illnesses in a variety of workplace settings. Common areas of practice include loneliness in old age, depression, dementia, Alzheimer's disease, vascular dementia, and Parkinson's disease.

<span class="mw-page-title-main">Alzheon</span>

Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts. The company is developing medicines for patients with Alzheimer's disease and other neurological and psychiatric disorders.

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion. The most common side effects of lecanemab include headache, infusion-related reactions and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid.

<span class="mw-page-title-main">Dementia and Alzheimer's disease in Australia</span> Major health issue in Australia

Dementia and Alzheimer's disease in Australia is a major health issue. Alzheimer's disease is the most common type of dementia in Australia. Dementia is an ever-increasing challenge as the population ages and life expectancy increases. As a consequence, there is an expected increase in the number of people with dementia, posing countless challenges to carers and the health and aged care systems. In 2018, an estimated 376,000 people had dementia; this number is expected to increase to 550,000 by 2030 and triple to 900,000 by 2050. The dementia death rate is increasing, resulting in the shift from fourth to second leading cause of death from 2006 to 2015. It is expected to become the leading cause of death over the next number of years. In 2011, it was the fourth leading cause of disease burden and third leading cause of disability burden. This is expected to remain the same until at least 2020.

<span class="mw-page-title-main">Experimental models of Alzheimer's disease</span>

Experimental models of Alzheimer's disease are organism or cellular models used in research to investigate biological questions about Alzheimer's disease as well as develop and test novel therapeutic treatments. Alzheimer's disease is a progressive neurodegenerative disorder associated with aging, which occurs both sporadically or due to familial passed mutations in genes associated with Alzheimer's pathology. Common symptoms associated with Alzheimer's disease include: memory loss, confusion, and mood changes.

The Women's Healthy Ageing Project (WHAP) is the longest ongoing medical research project examining the health of Australian women. Its landmark studies concern women's heart and brain health, a long-neglected area of specialised research.

<span class="mw-page-title-main">LY3372689</span> Chemical compound

LY3372689 is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase. Its result is to reduce formation of tau protein tangles.

Alzheimer's disease (AD) in African Americans is becoming a rising topic of interest in AD care, support, and scientific research, as African Americans are disproportionately affected by AD. Recent research on AD has shown that there are clear disparities in the disease among racial groups, with higher prevalence and incidence in African Americans than the overall average. Pathologies for Alzheimer’s also seem to manifest differently in African Americans, including with neuroinflammation markers, cognitive decline, and biomarkers. Although there are genetic risk factors for Alzheimer’s, these account for few cases in all racial groups.

References

  1. ↑ Belluck, Pam (2010-12-15). "National Alzheimer's Project Bill Passed by Congress". The New York Times. ISSN   0362-4331 . Retrieved 2019-11-03.
  2. ↑ "Senator Collins' Statement on NIH's Alzheimer's Research Budget | United States Senate Special Committee on Aging". www.aging.senate.gov. Retrieved 2019-11-05.
  3. ↑ The Lancet Neurology (2012-03-01). "A grand plan for Alzheimer's disease and related dementias". The Lancet Neurology. 11 (3): 201. doi:10.1016/S1474-4422(12)70026-1. ISSN   1474-4422. PMID   22341026. S2CID   45715123.
  4. 1 2 Egge, Robert (2014-04-01). "The Alzheimer's Study Group's Recommendations Five Years Later: Planning Has Advanced, But Agenda Remains Unfinished". Health Affairs. 33 (4): 555–560. doi:10.1377/hlthaff.2013.1377. ISSN   0278-2715. PMID   24711314.
  5. ↑ "A National Alzheimer's Strategic Plan: The Report of the Alzheimer's Study Group" (PDF). The Alzheimer's Association. Retrieved 5 November 2019.
  6. ↑ "National Alzheimer's Project Act". ASPE. 2015-09-29. Retrieved 2019-11-05.
  7. 1 2 "Possible Boost for U.S. Alzheimer's Research on Horizon | ALZFORUM". www.alzforum.org. Retrieved 2019-11-05.
  8. ↑ Kaiser, Jocelyn (2018-08-28). "The Alzheimer's gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease". Science | AAAS. Retrieved 2019-11-05.
  9. ↑ "Dementia plans | Alzheimer's Disease International". www.alz.co.uk. 2018-05-13. Retrieved 2019-11-05.
  10. ↑ Cahill, Suzanne (2019-01-02). "WHO's global action plan on the public health response to dementia: some challenges and opportunities". Aging & Mental Health. 24 (2): 197–199. doi: 10.1080/13607863.2018.1544213 . hdl: 2262/94174 . ISSN   1360-7863. PMID   30600688.
  11. ↑ "Achieving the WHO's Global Action Plan for Dementia". News-Medical.net. 2018-06-28. Retrieved 2019-11-05.
  12. ↑ "WHO global plan on dementia | Alzheimer's Disease International". www.alz.co.uk. 2019-03-23. Retrieved 2019-11-05.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.